CClinicalTrials.gg
CompletedNCT01322737SUMOUpdated Dec 16, 2014

Feasibility Trial to Evaluate the Ability of the SuMO Tissue Access and Resection System

An interventional study of Tissue Access and Resection System in Colon Disease and Gastric Disease, sponsored by University Hospitals Cleveland Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-12-16.

Sponsored by University Hospitals Cleveland Medical Center · Not applicable and Interventional

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This feasibility trial will evaluate the ability of the SuMO Tissue Access and Resection System (Apollo Endosurgery, Austin, Texas). The SuMO System utilizes balloons to create a submucosal pocket and electrosurgical cutting device to resect the mucosa. The SuMO elevates the tissue from the underlying muscularis using a balloon to distend the submucosa, similar to what is currently performed with injectable saline in a standard EMR. After dissection of the lesion, a separate cutting device will be utilized to resect the tissue by cutting around the border of the targeted tissue. If needed, a standard loop snare will be used to complete the mucosal resection.

Read the detailed description

The subject will already be scheduled for segmental colectomy or gastrectomy.

The colectomy or gastrectomy specimen will be prepared on a side table for an ex vivo endoscopic procedure. The ends of the stomach or colon, if not already stapled closed will be ligated to allow for insufflation. The endoscope will be placed into the excised organ and the SuMO System devices will be deployed away from any areas of excised pathologic tissue, so as not to disrupt the pathologist's evaluation of the excised tissue. The specimen will then be opened and grossly examined for the actual completeness of the submucosal pocket and resection. Mucosal and muscular wall disruptions will be assessed. Again, no interference in the underlying pathology will be performed. If sufficient specimen is present, the SuMO procedure may be repeated on the same specimen.

Following the performance of the EMR by the SUMO balloon system on the ex vivo colon specimen, both the resected piece of tissue and the site of resection will be evaluated pathologically by H and E staining. Specifically, the depth of resection in the ex vivo colon specimen will be determined. In addition, the level of dissection on the removed piece of mucosa will also be identified.

During this procedure still images or a video recording maybe captured, however all images will be taken of the removed specimen. There will not be any patient identifiers on any of the images or DVD's taken during the procedure.

No clinical follow up is required, as the treated area will have already been resected and there is no risk to the patient.

02

Conditions studied

  • Colon Disease
  • Gastric Disease

Keywords

  • resection
  • open
  • laparoscopic
  • benign
  • malignant
  • disease
  • colon
  • gastric
03

In context

Colonic Diseases

142 studies on the registry are indexed under Colonic Diseases; 22 are open to participants now.

This study's enrollment of 9 is below the median of 143 across 93 interventional studies indexed under Colonic Diseases.

Browse Colonic Diseases studies →

Lead sponsor

University Hospitals Cleveland Medical Center is the lead sponsor of 283 studies on the registry; 42 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 29 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Male or female over 18 years of age
  • Established indication for open or laparoscopic or colon resection or gastrectomy
  • Subject agrees to participate, fully understands content of informed consent form, and signs the informed consent form

Exclusion criteria

Exclusion Criteria:

  • Subjects that are minors or prisoners
  • Subjects who would have difficulty comprehending or complying with the requirements of the study
  • Subjects who fail to give informed consent
05

Study design

Phase
Not applicable
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    SUMO Tissue Access and Resection System

    Procedure: Tissue Access and Resection System

Interventions

  • ProcedureTissue Access and Resection System

    This feasibility trial will assess the effectiveness of SuMO System to create a submucosal pocket and resect the overlying mucosa in excised human colonic or gastric tissue

    Also known as: SUMO Tissue Access and Resection System

06

What researchers measure

Primary outcomes

  1. Evidence of the ability of the SUMO device to create a submucosal pocket and resect the overlying mucosa in human colon or stomach.

    Assess the feasibility of the SuMO device for creation of a submucosal pocket and resecting the overlying mucosa in a segment of excised human colon or stomach.

    Time frame: (day one)The colon or stomach tissue is evaluated in the Operating Room immediatley following excision. Subjects are not followed after using the excised tissue in the operating room.

07

Study locations

1 site
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01322737
Lead sponsor
University Hospitals Cleveland Medical Center
Collaborators
Apollo Endosurgery, Inc.
Responsible party
Jeffrey Marks, MD (Director, Surgical Endoscopy, University Hospitals Cleveland Medical Center) — Principal investigator
First posted
Mar 25, 2011
Start date
Jan 2011
Primary completion
Jun 2011
Completion
Jun 2011
Last update
Dec 16, 2014

Study contacts

Jeffrey Marks, MD
principal investigator · University Hospitals Cleveland Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion